Supplements and Featured Publications
Diving Into Therapeutic Decision-Making in Later-Line CLL
Volume: 1
Issue: 1
Molecular Testing and Evolving Treatment Strategies in HR+/HER2– Advanced Breast Cancer
Volume: 1
Issue: 1
The Evolution of Molecular Testing and Targeted Therapy in HR+/HER2– Breast Cancer
Volume: 1
Issue: 1
Treatment Considerations and Evolving Data in Advanced Melanoma After Checkpoint Inhibition
Volume: 1
Issue: 1
A dive into treatment considerations and ongoing research for advanced melanoma after PD-1 inhibition.
Furthering Treatment With Novel Therapies and Multidisciplinary Care in Advanced Melanoma After PD-1 Inhibition
Volume: 01
Issue: 01
Therapeutic Advances and AE Management in NF1-Associated Plexiform Neurofibromas
Volume: 1
Issue: 1
Defining Frontline Treatment Considerations in Advanced Urothelial Carcinoma
Volume: 1
Issue: 1
Moving the Needle With Checkpoint Inhibition in MCC and SCAC
Volume: 1
Issue: 1
2025 Genitourinary Cancers Symposium Priority Report
Volume: 1
Issue: 1
Perspectives on FDA Oncology Approvals and Withdrawals That Shaped 2024: A Year in Review Roundup
Volume: 1
Issue: 1
Treatment Trends in Adult and Pediatric Acute Lymphoblastic Leukemia
Volume: 1
Issue: 1
Treatment Trends and Ongoing Research in Acute Lymphoblastic Leukemia
Volume: 1
Issue: 1
Moving the Needle With JAK Inhibition in Myelofibrosis
Volume: 1
Issue: 1
Menin Inhibition Makes Waves for KMT2A-Rearranged AML
Volume: 1
Issue: 1
Managing Ocular and Other Adverse Effects Associated With Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
Volume: 1
Issue: 1
Dissecting Ongoing Research With Oncolytic Viruses in Melanoma
Volume: 1
Issue: 1
ASH 2024: Priority Report: Updates in Myeloproliferative Neoplasms
Volume: 1
Issue: 1
Experts detail updates in myeloproliferative neoplasms from the 2024 ASH Annual Meeting & Exposition.
Updates for BTK Inhibitors in CLL Around ASH 2024
Volume: 1
Issue: 1
Experts detail updates regarding BTK inhibitors in chronic lymphocytic leukemia around the 2024 ASH Annual Meeting.
Pancreatic Cancer Awareness Month: Updates in Ongoing Research in RAS Inhibition
Volume: 1
Issue: 1
Making the Most of MRD Assessment, Checkpoint Inhibition in Colorectal Cancer
Volume: 1
Issue: 1
Prostate Cancer Awareness Month: Updates in mCRPC and Radioligand Therapy
Volume: 1
Issue: 1
Exacting the Role of Novel Endocrine Therapies in ER+ Metastatic Breast Cancer
Volume: 1
Issue: 1
Taking Stock of Long-Term Data With TKIs in CML
Volume: 1
Issue: 1
Integrating the Glucocorticoid Receptor Pathway Into Ovarian Cancer Management
Volume: 1
Issue: 1
Harnessing the Activity of Targeted Therapy in HER2-Mutant NSCLC
Volume: 1
Issue: 1
ESMO 2024: Priority Report: Updates in Renal Cell Carcinoma
Volume: 1
Issue: 1
Research Efforts Seeking to Raise the Bar in Low-Risk MDS
Volume: 1
Issue: 1
Emerging Novel Therapies in Bladder Cancer
Volume: 1
Issue: 1
Novel Approaches in Treating HPV-Positive HNSCC
Volume: 1
Issue: 1
Research Efforts Are Underway in Advanced or Metastatic Epithelial Tumors
Volume: 1
Issue: 1
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5